Healthcare, Pharma & Life Sciences

Washington – October 17, 2026 -- Nearly half of patients with hormone receptor positive, HER2 negative advanced breast cancer develop resistance to first-line endocrine therapy driven by the ESR1 mutation (ESR1m), according to a new Academy of Managed Care Pharmacy (AMCP) Market Insights Program report. The report finds that biomarker testing and treatment paradigms are evolving faster than the evidence payers need to manage them.

Testing uncertainty drives inconsistent practice and coverage friction

Patients with ESR1m stay on ineffective treatment until radiologic progression is detected. Monitoring for the mutation with circulating tumor DNA (ctDNA) liquid biopsy before progression can enable an early switch to effective therapy and extend time on first-line treatment.

Pittsburgh – October 17, 2026 -- Allegheny Health Network (AHN) Cancer Center has launched RANDY'S Trial, a clinical study funded by a gala that raised $44,000 in 2025, to test whether existing medications can break down fibrosis that blocks surgery in patients with appendiceal and other peritoneal cancers.

The trial is formally titled Repurposed And Naturally-Derived Drugs for the Treatment of Fibrosis in Peritoneal Carcinomatosis. It is supported by The Randy & Stephanie Meyer Spread Goodness Fund and is named for the late Lt. Randy Meyer II, a City of Pittsburgh firefighter who battled a rare form of appendix cancer for more than a decade.

Eagan, Minnesota – October 17, 2026 -- Solventum (NYSE: SOLV) will release its third-quarter fiscal 2026 financial results on Thursday, October 17, 2026, after U.S. financial markets close.

Management hosts webcast directly after the November 5 release

Solventum management will hold a webcast following the release to discuss the results. The company said other forward-looking and material information may also be covered during the call, so the session may go beyond the reported figures.

Replay, slides and supplemental disclosures go on the investor relations site

A webcast replay, the earnings press release, presentation slides and supplemental financial disclosures will be available in the Investor Relations section of Solventum's website.

Jupiter, Florida – October 16, 2026 -- Myosin Therapeutics will present its first-in-class cancer candidate MT-125 at BioFuture 2026 in New York City on October 27–28, seeking investors and pharmaceutical partners to fund an extension into two additional treatment-resistant cancers.

CEO Courtney Miller joins oncology panel on October 27

Chief Executive Officer Courtney Miller, PhD, will speak on the panel "Beyond the Cure: The Brave New World of Revolutionary Cancer Therapeutics." The session covers next-generation cell therapies, AI-enabled cancer drug discovery, precision medicines and advanced therapeutic platforms. Participating CEOs will introduce their companies, followed by a moderated round-robin discussion.

Chief Medical Officer Karen Smith, MD, PhD, MBA, LLM, will join Miller for investor and strategic partner meetings throughout the conference.

MIAMI – October 16, 2026 -- Nicklaus Children's Hospital raised more than $4 million at its 19th Annual Diamond Ball on Saturday, October 10, funding the expansion of advanced specialized pediatric care for children and families across Florida and beyond.

Gala funds target specialized pediatric care expansion

The signature fundraising event drew community leaders, philanthropists, athletes and entertainment personalities. Radio co-hosts Enrique Santos and Dayanara Torres hosted the evening.

Allison W. Baker, President of Nicklaus Children's Hospital Foundation, said the proceeds will provide answers sooner, a specialist closer to home and treatment offering new hope to patients. Matthew A. Love, president and CEO of Nicklaus Children's Health System, said the gala is a major part of the system's ability to reach children in need of life-saving care.

Lansing – October 16, 2026 -- Niowave is building an 80,000-square-foot medical radioisotope production facility in Lansing, Michigan, with a capital investment of more than $85 million and operations expected to start in 2028.

Labor Secretary Keith Sonderling toured Niowave's existing dedicated production facility and the construction site of its second plant. He also held a roundtable with company leaders on the production of medical radioisotopes for cancer treatments.

New plant to house up to six linear particle accelerators

The facility will contain up to six new linear particle accelerators and expand Niowave's capacity to produce Actinium-225, an isotope used in targeted alpha therapies for cancer. It will also include production space, radiochemistry laboratories, warehousing and administrative offices.

Pleasanton – October 16, 2026 -- n6 Tec, Inc. has received ISO 13485:2016 certification from Intertek for its quality management system, covering the manufacture and service of genetic research instrumentation at its Pleasanton, California headquarters.

Certificate 0259003 runs through October 2029

Intertek issued the initial certificate on October 12, 2026. It is valid through October 11, 2029, subject to ongoing surveillance by the certification body.

ISO 13485:2016 is the international quality management standard for organizations that design, manufacture and service medical devices. An independent auditor must verify that documented processes for design controls, supplier management, manufacturing, traceability, corrective and preventive action, and customer feedback exist and are followed.

Orlando – October 16, 2026 -- Newsweek's America's Best Nursing Homes 2027 list ranked Solaris Healthcare East Orlando #19 and Solaris Healthcare Apopka #33 among facilities with 100-149 beds.

Newsweek and Statista screened 14,693 nursing homes to select 1,325

Newsweek compiles the ranking each year with research firm Statista. The 2027 edition highlights 1,325 of the 14,693 U.S. nursing homes analyzed, or about 9% of the field.

The evaluation draws on performance data, peer recommendations, accreditations and satisfaction metrics, and uses data from the Centers for Medicare & Medicaid Services (CMS).

Solaris places two Florida facilities in the 100-149 bed category

The East Orlando facility sits in Orlando, while the second ranked site is in Apopka, Florida. Both were listed in the same bed-size bracket, 100-149 beds.

Los Angeles – October 16, 2026 -- Fengate Private Equity, a division of Fengate Asset Management, has partnered with Clinical Research of West Florida (CRWF), an independent trial site operator with more than 1,000 completed trials, in a deal with undisclosed terms.

Westcove Partners, LLC acted as exclusive financial advisor to CRWF. Its deal team comprised Managing Directors Justin Hand and Abe M'Bodj, Director Bill Bolding, Vice President Geno Catalano and Associate Andrew Hartono.

CRWF runs three Phase I-IV facilities across Tampa Bay

Founded in 1995, CRWF operates three Phase I-IV facilities in the Tampa Bay area. The company has conducted more than 1,000 trials across a broad range of therapeutic areas and has differentiated expertise in complex autoimmune and rheumatology indications.

Alexandria, Va. – October 16, 2026 -- A wallet-sized CPR guidance patch from the University of Washington and a radiation-scatter device from the University of Pittsburgh School of Medicine took the $10,000 first prizes at the 2026 Collegiate Inventors Competition, which drew 25 students from nine U.S. colleges and universities.

Ten finalist teams, five undergraduate and five graduate, presented to a final-round panel of National Inventors Hall of Fame Inductees and U.S. Patent and Trademark Office (USPTO) officials. Winning teams receive cash awards plus a USPTO Patent Acceleration Certificate. The competition, established in 1990, is a program of the National Inventors Hall of Fame and is sponsored by the USPTO.